Hawaii 2023 Regular Session

Hawaii Senate Bill SR3 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	THE SENATE S.R. NO. 3 THIRTY-SECOND LEGISLATURE, 2023 STATE OF HAWAII SENATE RESOLUTION REQUESTING THE DEPARTMENT OF HEALTH TO CONVENE A MEDICINAL PSILOCYBIN AND PSILOCIN WORKING GROUP TO EXAMINE THE MEDICINAL AND THERAPEUTIC EFFECTS OF PSILOCYBIN AND PSILOCIN AND DEVELOP A LONG-TERM STRATEGIC PLAN TO ENSURE THE AVAILABILITY OF MEDICINAL PSILOCYBIN AND PSILOCIN OR PSILOCYBIN-BASED AND PSILOCIN-BASED PRODUCTS THAT ARE SAFE, ACCESSIBLE, AND AFFORDABLE FOR ELIGIBLE ADULT PATIENTS.
2	2
3	3	THE SENATE S.R. NO. 3
4	4	THIRTY-SECOND LEGISLATURE, 2023
5	5	STATE OF HAWAII
6	6
7	7	THE SENATE
8	8
9	9	S.R. NO.
10	10
11	11	3
12	12
13	13	THIRTY-SECOND LEGISLATURE, 2023
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29	SENATE RESOLUTION
30	30
31	31
32	32
33	33
34	34
35	35	REQUESTING THE DEPARTMENT OF HEALTH TO CONVENE A MEDICINAL PSILOCYBIN AND PSILOCIN WORKING GROUP TO EXAMINE THE MEDICINAL AND THERAPEUTIC EFFECTS OF PSILOCYBIN AND PSILOCIN AND DEVELOP A LONG-TERM STRATEGIC PLAN TO ENSURE THE AVAILABILITY OF MEDICINAL PSILOCYBIN AND PSILOCIN OR PSILOCYBIN-BASED AND PSILOCIN-BASED PRODUCTS THAT ARE SAFE, ACCESSIBLE, AND AFFORDABLE FOR ELIGIBLE ADULT PATIENTS.
36	36
37	37
38	38
39	39
40	40
41	41	WHEREAS, mental health conditions are treated in various ways depending on the condition and can include medication, therapy, and psychosocial services; and WHEREAS, these treatments, while effective for certain conditions and patients, do not treat all mental health conditions; and WHEREAS, psilocybin and psilocin occur naturally in certain species of mushrooms; and WHEREAS, psilocybin and psilocin are natural chemicals that can activate serotonin receptors in the brain; and WHEREAS, studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin and psilocin have shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including addiction, depression, anxiety disorders, and end-of-life psychological distress; and WHEREAS, the United States Food and Drug Administration has determined that preliminary clinical evidence indicates that psilocybin and psilocin may demonstrate substantial improvement over available therapies for major depressive disorder and severe treatment-resistant depression and has granted a breakthrough therapy designation for a treatment that uses psilocybin and psilocin as a therapy for these mental health conditions; and WHEREAS, Hawaii has a shortage of mental health professionals and should actively consider novel, innovative, and safe solutions to treat its citizens; now, therefore, BE IT RESOLVED by the Senate of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2023, that the Department of Health is requested to convene a Medicinal Psilocybin and Psilocin Working Group, to be placed in the Department of Health for administrative purposes; and BE IT FURTHER RESOLVED that the Medicinal Psilocybin and Psilocin Working Group is requested to examine: (1) Federal, state, and local laws, regulations, administrative rules, and procedures regarding the medicinal use of psilocybin and psilocin; (2) Available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin and psilocin in treating mental health conditions; and (3) Requirements, specifications, and guidelines for a medical professional to prescribe and provide psilocybin and psilocin to patients; and BE IT FURTHER RESOLVED that, if feasible, the Medicinal Psilocybin and Psilocin Working Group is requested to develop a long-term strategic plan to ensure the availability of medicinal psilocybin and psilocin or psilocybin-based and psilocin-based products that are safe, accessible, and affordable for adults twenty-one years of age or older; and BE IT FURTHER RESOLVED that the following individuals, or their respective designees, are requested to serve as members of the Medicinal Psilocybin and Psilocin Working Group: (1) The Director of Health, who is requested to serve as chair; (2) The Attorney General; (3) Faculty members from the University of Hawaii System with relevant scientific expertise; (4) The chairs of the Senate and House of Representatives standing committees whose subject matter purview is primarily responsible for reviewing legislation relating to health and the Judiciary; (5) A clinical practitioner licensed to prescribe psychotropic medication in the State of Hawaii; (6) A representative of the Drug Policy Forum of Hawaii, to be invited by the chair of the working group; (7) A representative of the Clarity Project, to be invited by the chair of the working group; (8) A representative of the Hawaii Psychiatric Medical Association, to be invited by the chair of the working group; and (9) A representative of the public with psychedelics‑related industry experience, to be invited by the chair of the working group; and BE IT FURTHER RESOLVED that the chair of the Medicinal Psilocybin and Psilocin Working Group may invite other interested parties with relevant experience to join the working group, provided that the working group does not exceed fifteen members; and BE IT FURTHER RESOLVED that the Medicinal Psilocybin and Psilocin Working Group is requested to submit a preliminary report of its findings and recommendations to the Legislature no later than twenty days prior to the convening of the Regular Session of 2024, and a final report of its findings and recommendations, including any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2025; and BE IT FURTHER RESOLVED that the Medicinal Psilocybin and Psilocin Working Group be dissolved on July 1, 2025; and BE IT FURTHER RESOLVED that certified copies of this Resolution be transmitted to the Director of Health, who in turn shall notify the non-governmental organizations represented in the working group; Attorney General; and President of the University of Hawaii. OFFERED BY: _____________________________ Report Title: Medical Psilocybin and Psilocin Working Group; Department of Health
42	42
43	43	WHEREAS, mental health conditions are treated in various ways depending on the condition and can include medication, therapy, and psychosocial services; and
44	44
45	45
46	46
47	47	WHEREAS, these treatments, while effective for certain conditions and patients, do not treat all mental health conditions; and
48	48
49	49
50	50
51	51	WHEREAS, psilocybin and psilocin occur naturally in certain species of mushrooms; and
52	52
53	53
54	54
55	55	WHEREAS, psilocybin and psilocin are natural chemicals that can activate serotonin receptors in the brain; and
56	56
57	57
58	58
59	59	WHEREAS, studies conducted by nationally and internationally recognized medical institutions indicate that psilocybin and psilocin have shown efficacy, tolerability, and safety in the treatment of a variety of mental health conditions, including addiction, depression, anxiety disorders, and end-of-life psychological distress; and
60	60
61	61
62	62
63	63	WHEREAS, the United States Food and Drug Administration has determined that preliminary clinical evidence indicates that psilocybin and psilocin may demonstrate substantial improvement over available therapies for major depressive disorder and severe treatment-resistant depression and has granted a breakthrough therapy designation for a treatment that uses psilocybin and psilocin as a therapy for these mental health conditions; and
64	64
65	65
66	66
67	67	WHEREAS, Hawaii has a shortage of mental health professionals and should actively consider novel, innovative, and safe solutions to treat its citizens; now, therefore,
68	68
69	69
70	70
71	71	BE IT RESOLVED by the Senate of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2023, that the Department of Health is requested to convene a Medicinal Psilocybin and Psilocin Working Group, to be placed in the Department of Health for administrative purposes; and
72	72
73	73
74	74
75	75	BE IT FURTHER RESOLVED that the Medicinal Psilocybin and Psilocin Working Group is requested to examine:
76	76
77	77
78	78
79	79	(1) Federal, state, and local laws, regulations, administrative rules, and procedures regarding the medicinal use of psilocybin and psilocin;
80	80
81	81
82	82
83	83	(2) Available medical, psychological, and scientific studies, research, and other information relating to the safety and efficacy of psilocybin and psilocin in treating mental health conditions; and
84	84
85	85
86	86
87	87	(3) Requirements, specifications, and guidelines for a medical professional to prescribe and provide psilocybin and psilocin to patients; and
88	88
89	89
90	90
91	91	BE IT FURTHER RESOLVED that, if feasible, the Medicinal Psilocybin and Psilocin Working Group is requested to develop a long-term strategic plan to ensure the availability of medicinal psilocybin and psilocin or psilocybin-based and psilocin-based products that are safe, accessible, and affordable for adults twenty-one years of age or older; and
92	92
93	93
94	94
95	95	BE IT FURTHER RESOLVED that the following individuals, or their respective designees, are requested to serve as members of the Medicinal Psilocybin and Psilocin Working Group:
96	96
97	97
98	98
99	99	(1) The Director of Health, who is requested to serve as chair;
100	100
101	101
102	102
103	103	(2) The Attorney General;
104	104
105	105
106	106
107	107	(3) Faculty members from the University of Hawaii System with relevant scientific expertise;
108	108
109	109
110	110
111	111	(4) The chairs of the Senate and House of Representatives standing committees whose subject matter purview is primarily responsible for reviewing legislation relating to health and the Judiciary;
112	112
113	113
114	114
115	115	(5) A clinical practitioner licensed to prescribe psychotropic medication in the State of Hawaii;
116	116
117	117
118	118
119	119	(6) A representative of the Drug Policy Forum of Hawaii, to be invited by the chair of the working group;
120	120
121	121
122	122
123	123	(7) A representative of the Clarity Project, to be invited by the chair of the working group;
124	124
125	125
126	126
127	127	(8) A representative of the Hawaii Psychiatric Medical Association, to be invited by the chair of the working group; and
128	128
129	129
130	130
131	131	(9) A representative of the public with psychedelics‑related industry experience, to be invited by the chair of the working group; and
132	132
133	133
134	134
135	135	BE IT FURTHER RESOLVED that the chair of the Medicinal Psilocybin and Psilocin Working Group may invite other interested parties with relevant experience to join the working group, provided that the working group does not exceed fifteen members; and
136	136
137	137
138	138
139	139	BE IT FURTHER RESOLVED that the Medicinal Psilocybin and Psilocin Working Group is requested to submit a preliminary report of its findings and recommendations to the Legislature no later than twenty days prior to the convening of the Regular Session of 2024, and a final report of its findings and recommendations, including any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2025; and
140	140
141	141
142	142
143	143	BE IT FURTHER RESOLVED that the Medicinal Psilocybin and Psilocin Working Group be dissolved on July 1, 2025; and
144	144
145	145
146	146
147	147	BE IT FURTHER RESOLVED that certified copies of this Resolution be transmitted to the Director of Health, who in turn shall notify the non-governmental organizations represented in the working group; Attorney General; and President of the University of Hawaii.
148	148
149	149
150	150
151	151
152	152
153	153
154	154
155	155	OFFERED BY: _____________________________
156	156
157	157
158	158
159	159	OFFERED BY:
160	160
161	161	_____________________________
162	162
163	163
164	164
165	165
166	166
167	167	Report Title:
168	168
169	169	Medical Psilocybin and Psilocin Working Group; Department of Health